Clinical Trial

AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer

Study acronym: ANGELICA

Withdrawn Phase 1/2

View on ClinicalTrials.gov →

Why the trial stopped

Molecule not available from the laboratory

Summary

The aim of this study is to determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of bemarituzimab given in combination with a fixed dose of bevacizumab and to assess the clinical activity of the proposed combination bemarituzumab and bevacizumab in 3 parallel and independent cohorts of gynecological cancer (endometrium, ovary and cervix).

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-08-21.

Status change: Not Yet Recruiting → Withdrawn 2026-04-20

Trial Details

NCT Number	NCT07146919
Lead Sponsor	Centre Leon Berard
Conditions	Endometrial Carcinoma, Ovarian Cancer, Cervix Cancer
Start Date	2025-10-15
Primary Completion	2030-10-15 (estimated)
Study Completion	2030-10-15 (estimated)
Updated on ClinicalTrials.gov	2026-04-23